Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk

Dow Jones

2025/12/27

11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

December 26, 2025 11:47 ET (16:47 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2594297111"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594297111\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594297111?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-27 00:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594297111","market":"nz","top_or_hot":-1,"title":"Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2025 11:47 ET (16:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-12-27 00:47</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2025 11:47 ET (16:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2594297111","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594297111","pubTimestamp":1766767620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","BK4139":"生物科技","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC"},"translate_title":"Biohaven的癫痫机会超过了抑郁症试验——市场讨论","themeId":"d018407bd33f27ba9ab8988ad29e6a0c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  December 26, 2025 11:47 ET (16:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}